Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.39 |
| ▸ | AHCY | P23526 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 4/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 5/20 | 0.35 |
| ▸ | DRD1 | P21728 | 3/20 | 0.35 |
| ▸ | DRD4 | P21917 | 3/20 | 0.35 |
| ▸ | DRD5 | P21918 | 3/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1027733 | 0.87 | NPY2R (0.38) | AHCYNPY2RHRH1 | |
| Hydrochloric Acid SCHEMBL1026921 | 0.86 | AHCY (0.38) | AHCYNPY2RHRH1 | |
| SCHEMBL1025650 | 0.81 | NPY2R (0.36) | AHCYNPY2R | |
| SCHEMBL1026373 | 0.80 | AHCY (0.51) | HRH3SIGMAR1AHCY | |
| SCHEMBL1025915 | 0.79 | AHCY (0.50) | HRH3SIGMAR1AHCY | |
| SCHEMBL1026030 | 0.77 | AHCY (0.46) | HRH3SIGMAR1AHCYOPRM1 | |
| SCHEMBL11955929 | 0.77 | AHCY (0.61) | AHCY | |
| Hydrochloric Acid SCHEMBL1026738 | 0.72 | AHCY (0.38) | AHCYDRD3 | |
| SCHEMBL1028031 | 0.71 | AHCY (0.42) | AHCYNPY2RHRH1 | |
| Hydrochloric Acid SCHEMBL1028279 | 0.70 | KDM4E (0.35) | AHCYDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2275404-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | HRH3 2873/4885SIGMAR1 3532/4885AHCY 4108/4885 |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | HRH3 2328/4885SIGMAR1 4091/4885AHCY 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.